Table 1.
Antigens |
F1 |
NH36 |
||||||
---|---|---|---|---|---|---|---|---|
Patients | Endemic controls (EC) | Asym.a | Cured cutaneous leishmaniasis (CCL) | CVL | EC | Asym. | CCL | CVL |
IFN-γ (pg/ml) | 58 | 147 | 195 | 231 | 37 | 126 | 156 | 135 |
TNF-α (pg/ml) | 451 | 448 | 357 | 906 | 232 | 254 | 285 | 516 |
IL-10 (pg/ml) | 117 | 109 | 114 | 141 | 94 | 102 | 101 | 140 |
IFN-γ/IL-10 ratio | 0.5 | 1.3 | 1.7 | 1.6 | 0.4 | 1.2 | 1.6 | 1 |
TNF-α/IL-10 ratio | 3.9 | 4.1 | 3.1 | 6.4 | 2.4 | 2.5 | 2.8 | 3.7 |
IFN-γ/IL-10 ratio % enrichment | 20 | 8 | 6 | 38 | – | – | – | – |
TNF-α/IL-10 ratio % enrichment | 38 | 39 | 10 | 42 | – | – | – | – |
Calculation was performed according to the following equation = (F1-NH36/F1) values × 100 = protective increment. doi: 10.1371/journal.pntd.0000866.t003.
aAsymptomatic.